Acceleron Pharma, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (22)

View All

Latest Posts

About This Stock More About This Stock
Acceleron Price Target Raised To $135 From $73 At Piper Sandler
Article By: The Fly
Tuesday, January 28, 2020 5:45 AM EST
Piper Sandler analyst Danielle Brill reiterates an Overweight rating on Acceleron shares.
In this article: XLRN
Read
Acceleron Downgraded To Neutral From Overweight At Piper Jaffray
Article By: The Fly
Tuesday, July 10, 2018 7:19 AM EST
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma to Neutral and lowered his price target for the shares to $52 from $55.
In this article: XLRN Also: CELG
Read
Biotechnology Stocks Preparing A New Bullish Trend
Article By: Taki Tsaklanos
Sunday, July 8, 2018 11:26 AM EST
Biotechnology stocks look bullish, and even more bullish than ever in the last three years.
In this article: IBB, ILMN, REGN, BIIB, CELG, XBI, ARRY, FOLD, SGMO, XLRN
Read
On The Fly: Top Stock Stories For Friday, June 29, 2018
Article By: The Fly
Friday, June 29, 2018 11:49 PM EST
Stocks opened in positive territory after taking their cue from European and Asian markets, which traded higher overnight. Here is a brief roundup of notable economic events, company news and the major movers of the week.
In this article: DB, GS, MS, NKE, CVG, SNX, GM, STZ, THC, CELG, XLRN, GEMP
Read
JPMorgan Upgrades Acceleron To Overweight Ahead Of Luspatercept Data
Article By: The Fly
Monday, February 26, 2018 9:07 AM EST
JPMorgan analyst Eric Joseph upgraded Acceleron Pharma to Overweight from Neutral and raised his price target for the shares to $52 from $33 ahead of pivotal data for lead asset luspatercept in myelodysplastic syndrome and beta-thalassemia.
In this article: XLRN
Read
All Posts

Latest Tweets for $XLRN

No tweets yet!